SCHEMBL228778

SCHEMBL228778

O=C(O)c1ccccc1-n1cccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.61
ALOX15 P16050 1/20 0.61
CYP2C9 P11712 1/20 0.61
CYP2C19 P33261 1/20 0.61
L3MBTL1 Q9Y468 3/20 0.56
POLB P06746 2/20 0.56
APEX1 P27695 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
MYC P01106 3/20 0.55
NR4A1 P22736 1/20 0.55
LMNA P02545 3/20 0.53
GAA P10253 1/20 0.53
KMT2A Q03164 1/20 0.53
AKR1C3 P42330 1/20 0.48
KDM4E B2RXH2 2/20 0.47
HPGD P15428 2/20 0.47
MAPK1 P28482 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CA12 O43570 1/20 0.46
CA1 P00915 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29671348 1.00 ALDH1A1 (0.61) ALDH1A1ALOX15CYP2C9CYP2C19L3MBTL1
Lithium SCHEMBL31310856 0.98 ALDH1A1 (0.59) ALDH1A1ALOX15CYP2C9CYP2C19L3MBTL1
SCHEMBL29479424 0.84 L3MBTL1 (0.50) ALDH1A1ALOX15CYP2C9CYP2C19L3MBTL1
SCHEMBL7441090 0.82 ALDH1A1 (0.50) ALDH1A1ALOX15CYP2C9CYP2C19L3MBTL1
SCHEMBL11766314 0.82 CYP2C19 (0.65) ALDH1A1CYP2C9CYP2C19L3MBTL1TDP1
SCHEMBL607557 0.81 ALDH1A1 (0.65) ALDH1A1CYP2C9CYP2C19L3MBTL1POLB
SCHEMBL702149 0.81 ALDH1A1 (0.59) ALDH1A1CYP2C9CYP2C19L3MBTL1POLB
Phthalic Acid SCHEMBL29653616 0.81 ALDH1A1 (0.93) ALDH1A1ALOX15L3MBTL1POLBAPEX1
SCHEMBL7773542 0.80 G6PD (0.53) ALDH1A1ALOX15CYP2C9CYP2C19L3MBTL1
Phthalic Acid SCHEMBL5668586 0.78 ALDH1A1 (1.00) ALDH1A1ALOX15POLBMYCNR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF Shenzhen Bay Laboratory (CN) 2023-05-25 US claimed
WO-2023088285-A1 SMALL MOLECULE INHIBITOR AGAINST NASOPHARYNGEAL CARCINOMA, PREPARATION METHOD FOR COMPOUND AND APPLICATION THEREOF 深圳湾实验室 2023-05-25 WO claimed
EP-4151621-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD THEREFOR AND USE THEREOF Shenzhen Bay Laboratory (CN) 2023-03-22 EP claimed
CN-107118773-A A kind of inorganic achirality quantum dot of gel load 国家纳米科学中心 2017-09-01 CN claimed
US-12391781-B2 Black particles, black coating material, coating film, and black matrix for color filters SEKISUI CHEMICAL CO., LTD. (JP) 2025-08-19 US disclosed
US-12378254-B2 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2025-08-05 US disclosed
EP-4063426-B1 BLACK PARTICLES, BLACK COATING MATERIAL, COATING FILM, AND BLACK MATRIX FOR COLOR FILTERS SEKISUI CHEMICAL CO LTD (JP) 2025-06-18 EP disclosed
US-12258314-B2 EBNA1 inhibitors and their method of use THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) 2025-03-25 US disclosed
CN-119390699-A Synthesis method of pyrrolo [1,2-a ] quinoxaline-4 (5H) -ketone compound 重庆文理学院 2025-02-07 CN disclosed
US-20240109901-A1 DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-04-04 US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 US disclosed
EP-0620216-A1 Benzamide derivatives and their use as vasopressin antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-10-19 EP disclosed
EP-0587188-A2 Aryl and heterocyclic substituted propenamide derivatives E.R. SQUIBB & SONS, INC. (US) 1994-03-16 EP disclosed
EP-0137333-B1 SPIRO-TRICYCLICAROMATIC SUCCINIMIDE DERIVATIVES AS INHIBITORS OF ALDOSE REDUCTASE ALCON LABORATORIES, INC. (US) 1992-12-30 EP disclosed
US-5153211-A Enzyme inhibitors ALCON LABORATORIES, INC. (US) 1992-10-06 US disclosed
US-5070100-A COMPLICATIONS OF DIABETES ALCON LABORATORIES, INC. (US) 1991-12-03 US disclosed
US-4864028-A ANTIDIABETIC AGENTS ALCON LABORATORIES, INC. (US) 1989-09-05 US disclosed
US-4537892-A ANTIDIABETIC AGENTS ALCON LABORATORIES, INC. (US) 1985-08-27 US disclosed
EP-0137333-A2 Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase ALCON LABORATORIES, INC. (US) 1985-04-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258314-B2 EBNA1 inhibitors and their method of use EBNA1BP2, MLLT1, PML ALDH1A1 3442/4885ALOX15 1501/4885CYP2C9 4374/4885
US-20230157996-A1 SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF SSB, EBNA1BP2, PML ALDH1A1 4846/4885ALOX15 3556/4885CYP2C9 4728/4885
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B ALDH1A1 3992/4885ALOX15 3436/4885CYP2C9 4573/4885
US-20240109901-A1 DISUBSTITUTED OCTAHYDROPYRROLO[3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS HCRTR2, HCRTR1, OXTR ALDH1A1 3132/4885ALOX15 719/4885CYP2C9 2554/4885
US-12378254-B2 Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators HCRTR2, HCRTR1, OXTR ALDH1A1 3132/4885ALOX15 719/4885CYP2C9 2554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.